Back to Trades
Sell4
Travere Therapeutics, Inc.
TVTX
Total Value
$115.4K
Net $115.4K sold
Sales
$115.4K
2 transactions
Company Information
- Company Name
- Travere Therapeutics, Inc.
- Ticker Symbol
- TVTX
- CIK
- 0001438533
Insider Information
- Role
- Insider
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- May 6, 2026
- Transaction Date
- May 4, 2026
- Accession Number
- 0001943192-26-000004
- Form Type
- 4
- Net Trading Amount
- -$115.4K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | 4,250 | — | Exercise | — |
| May 5, 2026 | Common Stock | 2,181 | $46.65 | Sale | $101.7K |
| May 6, 2026 | Common Stock | 310 | $43.95 | Sale | $13.6K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| May 4, 2026 | Derivative | 8,500 | — | Grant/Award | — |
| May 4, 2026 | Derivative | 4,250 | — | Exercise | — |
Footnotes
- (F1)On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.
- (F2)Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- (F3)This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
- (F4)Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.